Aliases & Classifications for Movement Disease

Aliases & Descriptions for Movement Disease:

Name: Movement Disease 12 29 14
Movement Disorders 52 41 42 69
Movement Disorder 14

Classifications:



External Ids:

Disease Ontology 12 DOID:480
MeSH 42 D009069
NCIt 47 C116757
SNOMED-CT 64 60342002
UMLS 69 C0026650

Summaries for Movement Disease

MedlinePlus : 41 imagine if parts of your body moved when you didn't want them to. if you have a movement disorder, you experience these kinds of impaired movement. dyskinesia is abnormal uncontrolled movement and is a common symptom of many movement disorders. tremors are a type of dyskinesia. nerve diseases cause many movement disorders, such as parkinson's disease. other causes include injuries, autoimmune diseases, infections and certain medicines. many movement disorders are inherited, which means they run in families. treatment varies by disorder. medicine can cure some disorders. others get better when an underlying disease is treated. often, however, there is no cure. in that case, the goal of treatment is to improve symptoms and relieve pain.

MalaCards based summary : Movement Disease, also known as movement disorders, is related to cervical dystonia and stereotypic movement disorder, and has symptoms including ataxia, athetosis and back pain. An important gene associated with Movement Disease is TOR1A (Torsin Family 1 Member A), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Circadian rythm related genes. The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and cellular

Related Diseases for Movement Disease

Diseases related to Movement Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
id Related Disease Score Top Affiliating Genes
1 cervical dystonia 31.9 ATP1A3 GCH1 SGCE TOR1A
2 stereotypic movement disorder 12.3
3 periodic limb movement disorder 12.2
4 extrapyramidal and movement disease 11.8
5 psychogenic movement 11.5
6 ocular motility disease 11.5
7 mirror movements 1 11.5
8 essential tremor 11.3
9 mental retardation, x-linked 102 11.2
10 dystonia 11.2
11 conversion disorder 11.1
12 blepharospasm 11.0
13 aromatic l-amino acid decarboxylase deficiency 10.9
14 neurodegeneration with brain iron accumulation 10.9
15 restless legs syndrome 10.9
16 neurodegeneration with brain iron accumulation 1 10.9
17 chorea, hereditary benign 10.9
18 supranuclear palsy, progressive 10.4
19 stiff-person syndrome 10.4
20 choreatic disease 10.4
21 focal hand dystonia 10.3 GCH1 SGCE TOR1A
22 obstructive sleep apnea 10.3 GCH1 SGCE TOR1A
23 microcephaly 12, primary, autosomal recessive 10.3 DRD2 SGCE TOR1A
24 bartholin's gland transitional cell carcinoma 10.3 GCH1 SGCE TOR1A
25 vipas39-related arthrogryposis, renal dysfunction, and cholestasis syndrome 10.3 GCH1 TH
26 lower gum cancer 10.3 LRRK2 SLC6A3 SNCA
27 multiple system atrophy 10.3 PARK7 PINK1 SNCA
28 parkinson disease 6, early onset 10.3 LRRK2 PARK7 PINK1
29 riedel's fibrosing thyroiditis 10.3 LRRK2 MAPT SNCA
30 femoral neuropathy 10.2 ATP1A3 MAPT SLC6A3
31 scrotum basal cell carcinoma 10.2 MAPT PANK2 SLC6A3
32 nephrogenic adenoma of the urethra 10.2 DRD2 SLC6A3 SNCA
33 corneal endothelial dystrophy 2, autosomal recessive 10.2 FTL PANK2 SNCA
34 anismus 10.2 DRD2 GCH1 SGCE TOR1A
35 ceroid lipofuscinosis, neuronal, 1 10.2 LRRK2 PARK7 PINK1 SNCA
36 lethal congenital contracture syndrome 8 10.2 LRRK2 PARK7 PINK1 SNCA
37 thrombosis 10.2 LRRK2 PARK7 PINK1 SNCA
38 trichothiodystrophy 3, photosensitive 10.2 LRRK2 PARK7 PINK1 SNCA
39 segmental dystonia 10.2 DRD2 FTL TOR1A
40 spastic paraplegia 44, autosomal recessive 10.2 GCH1 HTT PANK2 TOR1A
41 pyromania 10.2 DRD2 DRD3 SLC6A3
42 spinocerebellar ataxia, autosomal recessive 7 10.2 GCH1 TH
43 periampullary adenoma 10.2 ATP1A3 GCH1 SGCE SNCA TOR1A
44 lethal congenital contracture syndrome 1 10.2 GCH1 SGCE TH TOR1A
45 autoimmune disease of urogenital tract 10.2 LRRK2 MAPT SNCA
46 hereditary spastic paraplegia 51 10.2 FTL PANK2 SNCA
47 capos syndrome 10.2 ATP1A3 GCH1 PANK2 SGCE TOR1A
48 spink1-related hereditary pancreatitis 10.2 LRRK2 MAPT PARK7 SNCA
49 sphenoorbital meningioma 10.2 DRD2 DRD3 TH
50 plekhm1-related autosomal recessive osteopetrosis 10.2 LRRK2 MAPT PARK7 SNCA

Graphical network of the top 20 diseases related to Movement Disease:



Diseases related to Movement Disease

Symptoms & Phenotypes for Movement Disease

UMLS symptoms related to Movement Disease:


ataxia, athetosis, back pain, dystonia, headache, leg cramps, muscle cramp, myoclonus, pain, sciatica, seizures, spasm, syncope, torticollis, tremor, chronic pain, cogwheel rigidity, spasmodic torticollis, muscle fibrillation, asterixis, clumsiness, hyperexplexia, akathisia, involuntary movements, abnormal head movements, vertigo/dizziness, abnormal coordination, myokymia, sleeplessness, symptoms, pseudobulbar signs

MGI Mouse Phenotypes related to Movement Disease:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 GAMT HTT LRRK2 MAPT NKX2-1 PANK2
2 cellular MP:0005384 10.4 DRD2 FMR1 GAMT HTT LRRK2 MAPT
3 growth/size/body region MP:0005378 10.36 PARK7 PINK1 SLC2A1 SLC6A3 SNCA TH
4 homeostasis/metabolism MP:0005376 10.34 TOR1A ATP1A3 DRD2 DRD3 GAMT HTT
5 nervous system MP:0003631 10.25 SNCA TH TOR1A ATP1A3 DRD2 DRD3
6 mortality/aging MP:0010768 10.24 ATP1A3 DRD2 DRD3 GAMT HTT LRRK2
7 endocrine/exocrine gland MP:0005379 10.22 DRD2 FMR1 GAMT HTT LRRK2 NKX2-1
8 cardiovascular system MP:0005385 10.21 DRD2 DRD3 HTT LRRK2 MAPT NKX2-1
9 integument MP:0010771 10.01 DRD2 FMR1 HTT LRRK2 MAPT SLC6A3
10 no phenotypic analysis MP:0003012 9.91 LRRK2 MAPT NKX2-1 PINK1 SLC2A1 SNCA
11 normal MP:0002873 9.81 DRD2 HTT LRRK2 MAPT NKX2-1 SLC6A3
12 renal/urinary system MP:0005367 9.5 GAMT LRRK2 MAPT PANK2 SNCA DRD2
13 taste/olfaction MP:0005394 9.1 DRD2 HTT MAPT PINK1 SLC6A3 SNCA

Drugs & Therapeutics for Movement Disease

Drugs for Movement Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 957)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
3
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
5
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
6
Nicotine Approved Phase 4,Phase 1,Phase 2 54-11-5 942 89594
7
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1 136236-51-6 3052776
8
Bromocriptine Approved, Investigational Phase 4,Phase 3,Phase 2 25614-03-3 31101
9
Pramipexole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104632-26-0 59868 119570
10
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
11
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
12
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 91374-20-8, 91374-21-9 5095 497540
13
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2 123441-03-2 77991
14
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1 768-94-5 2130
15
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651 908828, 9651
16
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
17
Citalopram Approved Phase 4,Phase 2,Phase 3 59729-33-8 2771
18
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 2078-54-8 4943
19
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Phase 2 28523-86-6 5206
20
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2180-92-9, 38396-39-3 2474
21
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
22
Levobupivacaine Approved Phase 4 27262-47-1 92253
23
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
24
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 76-42-6 5284603
25
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
26
Lactulose Approved Phase 4,Phase 3,Phase 2 4618-18-2 11333
27
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
28
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
29
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
30
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2 76631-46-4, 113775-47-6 68602 5311068 56032
31
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
32
Remifentanil Approved Phase 4,Phase 3,Phase 1,Phase 2 132875-61-7 60815
33
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2 169590-42-5 2662
34 Parecoxib Approved Phase 4,Phase 2 198470-84-7
35
Tramadol Approved, Investigational Phase 4,Phase 1,Phase 2 27203-92-5 33741
36
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 60142-96-3 3446
37
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 437-38-7 3345
39
Terbutaline Approved Phase 4 23031-25-6 5403
40
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2 41372-20-7, 58-00-4 6005
41
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1 28860-95-9 34359 38101
42
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130929-57-6 5281081
43
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
44
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
45 Piracetam Approved Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
46
Ibuprofen Approved Phase 4,Phase 3,Phase 2 15687-27-1 3672
47
Ropivacaine Approved Phase 4,Phase 3,Phase 2 84057-95-4 71273 175805
48
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
49
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
50
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386

Interventional clinical trials:

(show top 50) (show all 5172)
id Name Status NCT ID Phase
1 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4
2 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4
3 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
4 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4
5 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4
6 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4
7 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4
8 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4
9 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
10 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4
11 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
12 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
13 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4
14 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4
15 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4
16 Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease Unknown status NCT01673724 Phase 4
17 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4
18 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4
19 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4
20 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4
21 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4
22 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4
23 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4
24 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
25 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4
26 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Unknown status NCT01860196 Phase 4
27 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4
28 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4
29 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
30 Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy Unknown status NCT01052337 Phase 4
31 The Analgesic Efficacy of Local Anaesthetic Wound Infiltration Versus Intrathecal Morphine for Total Knee Replacement Unknown status NCT01312415 Phase 4
32 Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery Unknown status NCT01536717 Phase 4
33 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4
34 The Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic for Total Hip Replacement Unknown status NCT01312077 Phase 4
35 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4
36 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
37 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4
38 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
39 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4
40 Memantine for Post-Operative Pain Control Unknown status NCT01041313 Phase 4
41 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4
42 Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit Unknown status NCT00862160 Phase 4
43 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4
44 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
45 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
46 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4
47 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
48 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
49 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
50 Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis Unknown status NCT00144820 Phase 4

Search NIH Clinical Center for Movement Disease

Cochrane evidence based reviews: movement disorders

Genetic Tests for Movement Disease

Genetic tests related to Movement Disease:

id Genetic test Affiliating Genes
1 Abnormality of Movement 29

Anatomical Context for Movement Disease

Publications for Movement Disease

Articles related to Movement Disease:

id Title Authors Year
1
Muscle co-activity tuning in Parkinsonian hand movement: disease-specific changes at behavioral and cerebral level. ( 26300761 )
2015

Variations for Movement Disease

Copy number variations for Movement Disease from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 262562 X 37500000 47300000 Deletion MAOA Movement disorder
2 262566 X 37500000 47300000 Deletion MAOB Movement disorder

Expression for Movement Disease

Search GEO for disease gene expression data for Movement Disease.

Pathways for Movement Disease

GO Terms for Movement Disease

Cellular components related to Movement Disease according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.88 LRRK2 PARK7 SLC2A1 SLC6A3
2 cytoplasmic vesicle membrane GO:0030659 9.81 HTT SNCA TH TOR1A
3 neuronal cell body GO:0043025 9.8 ATP1A3 LRRK2 MAPT SLC6A3 SNCA TH
4 cell body GO:0044297 9.77 MAPT PARK7 PINK1
5 perikaryon GO:0043204 9.76 DRD2 FMR1 LRRK2 TH
6 mitochondrial intermembrane space GO:0005758 9.74 PANK2 PARK7 PINK1
7 presynapse GO:0098793 9.73 FMR1 PARK7 SLC6A3
8 synaptic vesicle GO:0008021 9.73 LRRK2 SNCA TH TOR1A
9 neuron projection GO:0043005 9.73 FMR1 LRRK2 PARK7 SLC6A3 TH TOR1A
10 terminal bouton GO:0043195 9.71 LRRK2 SNCA TH
11 axon terminus GO:0043679 9.7 DRD2 FMR1 SNCA
12 postsynapse GO:0098794 9.67 FMR1 LRRK2 SNCA
13 autolysosome GO:0044754 9.55 FTL LRRK2
14 growth cone GO:0030426 9.55 FMR1 LRRK2 MAPT SNCA TOR1A
15 inclusion body GO:0016234 9.54 HTT LRRK2 SNCA
16 dendrite GO:0030425 9.5 DRD2 FMR1 HTT LRRK2 MAPT SGCE
17 axon GO:0030424 9.36 ATP1A3 DRD2 FMR1 HTT LRRK2 MAPT
18 cytosol GO:0005829 10.32 FMR1 FTL GAMT GCH1 HTT LRRK2
19 cytoplasm GO:0005737 10.31 ATP1A3 FMR1 GAMT GCH1 HTT LRRK2
20 cell projection GO:0042995 10.06 DRD3 FMR1 LRRK2 MAPT SGCE TOR1A
21 synapse GO:0045202 10 ATP1A3 FMR1 LRRK2 SNCA TOR1A

Biological processes related to Movement Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.93 DRD2 DRD3 SLC6A3 TH
2 response to drug GO:0042493 9.93 ATP1A3 DRD2 DRD3 SLC6A3 SNCA TH
3 mitochondrion organization GO:0007005 9.89 LRRK2 PARK7 PINK1
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.86 PARK7 PINK1 SNCA
5 negative regulation of protein phosphorylation GO:0001933 9.85 LRRK2 PARK7 SNCA
6 memory GO:0007613 9.85 ATP1A3 MAPT TH
7 adult locomotory behavior GO:0008344 9.83 ATP1A3 PARK7 SNCA
8 cellular response to oxidative stress GO:0034599 9.83 LRRK2 PARK7 PINK1 SNCA
9 negative regulation of neuron death GO:1901215 9.82 LRRK2 PARK7 SNCA
10 visual learning GO:0008542 9.82 ATP1A3 DRD2 DRD3
11 response to nicotine GO:0035094 9.81 DRD2 SLC6A3 TH
12 regulation of mitochondrial membrane potential GO:0051881 9.76 PANK2 PARK7 PINK1
13 negative regulation of blood pressure GO:0045776 9.75 DRD2 DRD3 GCH1
14 response to amphetamine GO:0001975 9.74 DRD2 DRD3 TH
15 regulation of neurotransmitter secretion GO:0046928 9.72 FMR1 SNCA
16 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A3 TH
17 microglial cell activation GO:0001774 9.72 MAPT SNCA
18 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 DRD3
19 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD3
20 supramolecular fiber organization GO:0097435 9.71 MAPT SNCA
21 negative regulation of macroautophagy GO:0016242 9.71 LRRK2 PINK1
22 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD2 FMR1
23 negative regulation of oxidative stress-induced neuron death GO:1903204 9.7 PARK7 PINK1
24 negative regulation of autophagosome assembly GO:1902902 9.7 LRRK2 PINK1
25 G-protein coupled receptor internalization GO:0002031 9.7 DRD2 DRD3
26 synaptic vesicle transport GO:0048489 9.69 SNCA TOR1A
27 regulation of phosphoprotein phosphatase activity GO:0043666 9.69 DRD2 HTT
28 regulation of dopamine secretion GO:0014059 9.69 DRD2 DRD3 SNCA
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD3
30 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.68 LRRK2 PARK7
31 adenohypophysis development GO:0021984 9.68 DRD2 SLC6A3
32 positive regulation of mitophagy GO:1903599 9.67 HTT PARK7
33 intracellular distribution of mitochondria GO:0048312 9.67 LRRK2 MAPT
34 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD3 SNCA
35 response to cocaine GO:0042220 9.67 DRD2 DRD3 SLC6A3 SNCA
36 regulation of mitochondrial fission GO:0090140 9.66 LRRK2 MAPT
37 regulation of cAMP metabolic process GO:0030814 9.66 DRD2 DRD3
38 cellular response to manganese ion GO:0071287 9.65 LRRK2 TH
39 dopamine metabolic process GO:0042417 9.65 DRD2 DRD3 SNCA
40 locomotory behavior GO:0007626 9.65 DRD2 DRD3 NKX2-1 SLC6A3 TH
41 positive regulation of dopamine receptor signaling pathway GO:0060161 9.63 DRD3 LRRK2
42 regulation of synaptic vesicle transport GO:1902803 9.62 LRRK2 PINK1
43 negative regulation of mitochondrial fission GO:0090258 9.62 MAPT PINK1
44 negative regulation of oxidative stress-induced cell death GO:1903202 9.61 PARK7 PINK1
45 negative regulation of dopamine receptor signaling pathway GO:0060160 9.61 DRD2 DRD3
46 prepulse inhibition GO:0060134 9.61 DRD2 DRD3 SLC6A3
47 acid secretion GO:0046717 9.6 DRD2 DRD3
48 response to histamine GO:0034776 9.59 DRD2 DRD3
49 regulation of locomotion GO:0040012 9.58 DRD3 LRRK2 SNCA
50 negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway GO:1903384 9.56 PARK7 PINK1

Molecular functions related to Movement Disease according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.91 DRD2 FMR1 GCH1 LRRK2 MAPT PARK7
2 microtubule binding GO:0008017 9.76 FMR1 LRRK2 MAPT SNCA
3 kinase binding GO:0019900 9.7 HTT PARK7 SLC2A1
4 drug binding GO:0008144 9.67 DRD2 DRD3 SLC6A3
5 enzyme binding GO:0019899 9.65 MAPT NKX2-1 PARK7 SNCA TH
6 identical protein binding GO:0042802 9.61 DRD2 FMR1 FTL HTT LRRK2 MAPT
7 ferric iron binding GO:0008199 9.51 FTL TH
8 dynactin binding GO:0034452 9.48 HTT MAPT
9 D1 dopamine receptor binding GO:0031748 9.4 ATP1A3 DRD3
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD3
11 cuprous ion binding GO:1903136 9.32 PARK7 SNCA
12 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD2 DRD3
13 dopamine binding GO:0035240 8.92 DRD2 DRD3 SLC6A3 TH

Sources for Movement Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....